Preview

Rational Pharmacotherapy in Cardiology

Advanced search

CLINICAL APPROACHES TO INTERPRETATION OF CLINICAL TRAILS RESULTS ON BETA-BLOCKERS FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEART FAILURE

https://doi.org/10.20996/1819-6446-2010-6-2-201-205

Full Text:

Abstract

Modern approaches to a choice of beta-blockers for treatment of patients with chronic heart failure depending on the statistical and clinical significance of randomized clinical trails results are considered. Beta-blocker «class-effect» is discussed in context of beta-blocker therapeutic tactics. Data about bisoprolol usage for prevention of sudden death in patients with left ventricle systolic dysfunction is also presented.

About the Authors

S. R. Giljarevskiy
Research Institute for Emergency Medical Care named after N.V. Sklifosofsky
Russian Federation

Emergency cardiac care unit for the patients with acute myocardial infarction

Bolshaya Sukcharevskaya pl. 3, Moscow, 129090


I. M. Kuzmina
Research Institute for Emergency Medical Care named after N.V. Sklifosofsky
Russian Federation

Emergency cardiac care unit for the patients with acute myocardial infarction

Bolshaya Sukcharevskaya pl. 3, Moscow, 129090


References

1. Anderson J.L., Krause-Steinrauf H., Goldman S. et al. Failure of benefit and early hazard of bucindolol for Class IV heart failure. J Card Fail 2003;9(4):266-77.

2. FlatherM.D., ShibataM.C.,CoatsA.J. et al. Randomized trialto determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26(3):215-25.

3. Kaul S., Diamond G.A. Trial and Error. How to Avoid Commonly Encountered Limitations of Published Clinical Trials. J Am Coll Cardiol 2010;55(5):415-27.

4. Willenheimer R., van Veldhuisen D.J., Silke B. et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence. Results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005;112(16):2426-35.

5. Swedberg K., Cleland J.,DargieH. et al. Guidelines forthe diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur Heart J 2005;26(11):1115-40.

6. Hunt S.A., Baker D.W., Chin M.H. et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/AmericanHeartAssociation Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America. Circulation 2001;104(24):2996- 3007.

7. Garg R., Yusuf S. Overview ofrandomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273(18):1450-6.

8. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomized trial. Lancet 1999;353(9146):9-13.

9. MERIT-HF Study group. Effect of metoprolol CR/XL in chronic heartfailure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 1999; 353(9169):2001-7.

10. Packer M., Coats A.J., Fowler M.B. et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344(2):1651-8.

11. Cleland J.G., Cohen-Solal A., Aguilar J.C. et al; IMPROVEMENT ofHeart Failure Programme Committees and Investigators. Improvement programme in evaluation and management; Study Group on Diagnosis of the Working Group on Heart Failure of The European Society of Cardiology. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet 2002;360(9346):1631-9.

12. Davies M., Hobbs F., Davis R. et al. Prevalence of left-ventricular systolic dysfunction and heartfailure in the Echocardiographic Heart of England Screening study: a population based study. Lancet 2001;358(9280):439-44.

13. Packer M. Pathophysiology of heart failure. Lancet 1992;340(8811):88-95.

14. Campbell D.J., Aggarwal A., Esler M., Kaye D. Beta-blockers, angiotensin II, and ACE inhibitors in patients with heart failure. Lancet 2001;358(9293):1609-10.

15. Teisman A.C., van Veldhuisen D.J., Boomsma F. et al. Chronic beta-blocker treatment in patients with advanced heartfailure: effects on neurohormones. IntJ Cardiol 2000;73(1):7- 14.

16. Uretsky B.F., Sheahan R.G. Primary prevention of sudden cardiac death in heart failure: will the solution be shocking? J Am Coll Cardiol 1997;30(7):1589-97.

17. Huikuri H.V., Castellanos A., Myerburg R.J. Sudden death due to cardiac arrhythmias. N Engl J Med 2001;345(20):1473-82.

18. Lane R.E., Cowie M.R., Chow A.W. Prediction and prevention of sudden cardiac death in heart failure. Heart 2005(5);91:674-80.

19. DobreD., vanVeldhuisenD.J., GoulderM.A. et al.Clinical effects ofinitial6 months monotherapy with bisoprolol versus enalapril in the treatment of patients with mild to moderate chronic heart failure. Data from the CIBIS III Trial. Cardiovasc Drugs Ther 2008;22(5):399-405.

20. Poole-Wilson P.A., Uretsky B.F., Thygesen K. et al. Mode of death in heart failure: findings from the ATLAS trial. Heart 2003;89(1):42-8.

21. Simon T., Mary-Krause M., Funck-Brentano C. et al. Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study(CIBIS II). Eur Heart J 2003;24(6):552-9.

22. Wikstrand J., Hjalmarson A., Waagstein F. et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol 2002;40(3):491-8.

23. McAlister F.A., Wiebe N., Ezekowitz J.A. et al. Meta-analysis: beta-blocker dose, heartrate reduction, and death in patients with heart failure. Ann Intern Med 2009;150(11):784- 94

24. Cleland J.G., Coletta A.P., Torabi A., Clark A.L. Clinical trials update from the European Society of Cardiology heart failure meeting 2009: CHANCE, B-Convinced, CHAT, CIBIS-ELD, and Signal-HF. Eur J Heart Fail 2009;11(8):802-5.

25. de Groote P., Isnard R., Assyag P. et al. Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey. Eur J Heart Fail 2007;9(12):1205-11.

26. de Groote P., Isnard R., Clerson P. et al. Improvement in the management of chronic heart failure since the publication of the updated guidelines of the European Society of Cardiology. The Impact-Reco Programme. Eur J Heart Fail 2009;11(1):85-91.

27. Dunkelgrun M., Boersma E., Schouten O. et al. Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients undergoing noncardiovascular surgery: a randomized controlled trial (DECREASE￾IV). Ann Surg 2009;249(6):921-926.

28. POISE Study Group,Devereaux P.J., YangH., Yusuf S. et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008;371(9627):1839-47.


For citation:


Giljarevskiy S.R., Kuzmina I.M. CLINICAL APPROACHES TO INTERPRETATION OF CLINICAL TRAILS RESULTS ON BETA-BLOCKERS FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEART FAILURE. Rational Pharmacotherapy in Cardiology. 2010;6(2):201-205. (In Russ.) https://doi.org/10.20996/1819-6446-2010-6-2-201-205

Views: 362


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)